drugset

drugset / Trial / NCT07330778

A Study of CDX-622 in Participants With Mild to Moderate Asthma

NCT07330778 ↗

Phase 1 Recruiting 12 enrolled Celldex Therapeutics

NaSingle-groupOpen-labelTreatment

Summary

This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.

Timeline

Start: 2026-06-01
Primary completion: 2027-03
Completion: 2027-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CDX-622	Unknown	—	Intravenous

Indications